These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 21624110)

  • 1. MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines.
    Ohnstad HO; Paulsen EB; Noordhuis P; Berg M; Lothe RA; Vassilev LT; Myklebost O
    BMC Cancer; 2011 May; 11():211:1-11. PubMed ID: 21624110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.
    Pishas KI; Neuhaus SJ; Clayer MT; Schreiber AW; Lawrence DM; Perugini M; Whitfield RJ; Farshid G; Manavis J; Chryssidis S; Mayo BJ; Haycox RC; Ho K; Brown MP; D'Andrea RJ; Evdokiou A; Thomas DM; Desai J; Callen DF; Neilsen PM
    Cancer Res; 2014 Feb; 74(3):921-31. PubMed ID: 24336067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nutlin-3a is a potential therapeutic for ewing sarcoma.
    Pishas KI; Al-Ejeh F; Zinonos I; Kumar R; Evdokiou A; Brown MP; Callen DF; Neilsen PM
    Clin Cancer Res; 2011 Feb; 17(3):494-504. PubMed ID: 21098696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.
    Müller CR; Paulsen EB; Noordhuis P; Pedeutour F; Saeter G; Myklebost O
    Int J Cancer; 2007 Jul; 121(1):199-205. PubMed ID: 17354236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals.
    Candido S; Abrams SL; Steelman LS; Lertpiriyapong K; Martelli AM; Cocco L; Ratti S; Follo MY; Murata RM; Rosalen PL; Bueno-Silva B; de Alencar SM; Lombardi P; Mao W; Montalto G; Cervello M; Rakus D; Gizak A; Lin HL; Libra M; Akula SM; McCubrey JA
    Adv Biol Regul; 2019 May; 72():22-40. PubMed ID: 30898612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
    Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
    Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.
    Crane EK; Kwan SY; Izaguirre DI; Tsang YT; Mullany LK; Zu Z; Richards JS; Gershenson DM; Wong KK
    PLoS One; 2015; 10(8):e0135101. PubMed ID: 26248031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a.
    Duan L; Perez RE; Chen L; Blatter LA; Maki CG
    J Mol Cell Biol; 2018 Aug; 10(4):331-340. PubMed ID: 29190376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.
    Koster R; Timmer-Bosscha H; Bischoff R; Gietema JA; de Jong S
    Cell Death Dis; 2011 Apr; 2(4):e148. PubMed ID: 21509038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.
    Tabe Y; Sebasigari D; Jin L; Rudelius M; Davies-Hill T; Miyake K; Miida T; Pittaluga S; Raffeld M
    Clin Cancer Res; 2009 Feb; 15(3):933-42. PubMed ID: 19188164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
    Hasegawa H; Yamada Y; Iha H; Tsukasaki K; Nagai K; Atogami S; Sugahara K; Tsuruda K; Ishizaki A; Kamihira S
    Leukemia; 2009 Nov; 23(11):2090-101. PubMed ID: 19710698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
    Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
    Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
    Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme.
    Villalonga-Planells R; Coll-Mulet L; Martínez-Soler F; Castaño E; Acebes JJ; Giménez-Bonafé P; Gil J; Tortosa A
    PLoS One; 2011 Apr; 6(4):e18588. PubMed ID: 21483692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.
    Sriraman A; Radovanovic M; Wienken M; Najafova Z; Li Y; Dobbelstein M
    Oncotarget; 2016 May; 7(22):31623-38. PubMed ID: 27183917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
    Gamble LD; Kees UR; Tweddle DA; Lunec J
    Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.
    Zheng T; Wang J; Song X; Meng X; Pan S; Jiang H; Liu L
    J Cancer Res Clin Oncol; 2010 Oct; 136(10):1597-604. PubMed ID: 20174822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
    Künkele A; De Preter K; Heukamp L; Thor T; Pajtler KW; Hartmann W; Mittelbronn M; Grotzer MA; Deubzer HE; Speleman F; Schramm A; Eggert A; Schulte JH
    Neuro Oncol; 2012 Jul; 14(7):859-69. PubMed ID: 22591662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
    Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
    Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.